BRI2 inhibits amyloid β-peptide precursor protein processing by interfering with the docking of secretases to the substrate

86Citations
Citations of this article
90Readers
Mendeley users who have this article in their library.

Abstract

Genetic alterations of amyloid β-peptide (Aβ) production caused by mutations in the Aβ precursor protein (APP) cause familial Alzheimer's disease (AD). Mutations in BRI2, a gene of undefined function, are linked to familial British and Danish dementias, which are pathologically and clinically similar to Alzheimer's disease. We report that BRI2 is a physiological suppressor of Aβ production. BRI2 restrict docking of γ-secretase to APP and access of α- and β-secretases to their cleavage APP sequences. Alterations of BRI2 by gene targeting or transgenic expression regulate Aβ levels and AD pathology in mouse models of AD. Competitive inhibition of APP processing by BRI2 may provide a new approach to AD therapy and prevention. Copyright © 2008 Society for Neuroscience.

Cite

CITATION STYLE

APA

Matsuda, S., Giliberto, L., Matsuda, Y., McGowan, E. M., & D’Adamio, L. (2008). BRI2 inhibits amyloid β-peptide precursor protein processing by interfering with the docking of secretases to the substrate. Journal of Neuroscience, 28(35), 8668–8676. https://doi.org/10.1523/JNEUROSCI.2094-08.2008

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free